Adicet Bio Inc (ACET)
NASDAQ:ACET
Want to see ACET full AI Analyst Report?
ACET Stock Chart & Stats
$8.22
-$0.04(-4.07%)
At close: 4:00 PM EST
$8.22
-$0.04(-4.07%)
Day’s Range― - ―
52-Week Range$6.01 - $17.43
Previous CloseN/A
Volume197.46K
Average Volume (3M)103.09K
Market Cap
$75.25M
Enterprise Value$64.69M
Total Cash (Recent Filing)$137.59M
Total Debt (Recent Filing)$13.90M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 06, 2026EPS Estimate
-2.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.90
Shares Outstanding9,348,236
10 Day Avg. Volume80,798
30 Day Avg. Volume103,088
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-48.20
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$21.80Price Target Upside165.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-8.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityLow absolute debt and a debt-to-equity near 0.10 materially reduce refinancing pressure and give the company financial flexibility. This durable strength lowers near-term solvency risk and preserves optionality to fund R&D, partnerships, or manufacturing scale-up despite operating losses.
Allogeneic Γδ T‑cell PlatformA focus on allogeneic (off-the-shelf) gamma-delta T cell therapies provides a structural competitive advantage versus autologous approaches. If clinically validated, it supports centralized manufacturing, faster patient access, and easier partnering/commercial scale, making long-term revenue models more scalable.
Institutional Investor Support / Flexible CapitalThe private exchange with RA Capital creating a pre-funded warrant indicates institutional willingness to remain invested and provides a flexible capitalization mechanism. Such structured support can extend runway or enable staged participation without immediate concentrated control.
Bears Say
High Cash Burn / Weak Cash GenerationSustained operating and free cash outflows near $90M TTM reflect structural cash consumption that will deplete liquidity absent material progress. Persistent burn forces repeated financing or partnership transactions, raising dilution risk and constraining long-term strategic options.
No Revenue / Loss-making OperationsThe company reports zero product revenue and a sizable net loss, signaling an absence of commercial validation. Without revenue, the business cannot self-fund operations; long-term viability depends on successful clinical development, regulatory approval, or partner commercialization.
Declining Equity Base / Reliance On FinancingA falling equity base reflects accumulated losses and repeated capital activity, reducing the capital cushion available for setbacks. This structural trend increases dependence on external financing, heightens dilution risk, and weakens resilience to operational or clinical delays.
Adicet Bio News
ACET FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest stock price was $6.01 and its highest was $17.43 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $75.25M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on May 13, 2026. The company reported -$1.88 earnings per share for the quarter, beating the consensus estimate of -$3.076 by $1.196.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc pays a Quarterly dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Adicet Bio Inc dividends here
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -2.18.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,348,236 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$1.88 in its last earnings report, beating expectations of -$3.076. Following the earnings report the stock price went up 4.213%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in ACET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.80 (165.21% Upside)
$21.80 (165.21% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 77.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $929.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.43%
12-Months-Change
Fundamentals
Return on Equity
-80.35%
Trailing 12-Months
Asset Growth
-11.44%
Trailing 12-Months
Company Description
Adicet Bio Inc
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET Stock 12 Month Forecast
Average Price Target
$21.80
▲(165.21% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
20.11% Insiders
9.72% Mutual Funds
44.52% Other Institutional Investors
22.11% Public Companies and
Individual Investors